One-Shot gene therapy could slash bleeding in hemophilia a
Disease control
Recruiting now
This study tests a single-dose gene therapy called GS1191-0445 for adults with hemophilia A, a bleeding disorder. The therapy uses a harmless virus to deliver a working gene to the liver, helping the body produce its own clotting factor. Researchers will measure how well it reduc…
Phase: PHASE3 • Sponsor: Gritgen Therapeutics Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC